PF-05280586 vs Rituximab

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Rheumatoid Arthritis

Shared mechanism: CD20 · full Rheumatoid Arthritis pipeline

PF-05280586

Marketed by Pfizer

Approved in Rheumatoid Arthritisbiologic (registry-typed, subtype undisclosed)
Partial signal

NCT01526057 · Phase 2 · completed

The 220-participant trial was randomized, quadruple-blind, and actively controlled with European- and US-sourced rituximab. The primary pharmacokinetic comparisons met the prespecified equivalence range for both peak concentration and total drug exposure, but these were surrogate measures rather than hard clinical outcomes, supporting a moderate evidence grade.

Reported efficacy

Maximum Serum Concentration (Cmax) of Rituximab (Predose (Day 1) and 3, 4.25 (immediately before 1st infusion end), 72, 168, 335 (Day 15 within 1.5 hours before 2nd infusion), 337.5, 339.25 (Day 15 immediately before 2nd infusion end), 408, 504, 672, 1344, and 2016 hours after start of 1st infusion); AUC 0-inf of Rituximab (Predose (Day 1) and 3, 4.25 (immediately before 1st infusion end), 72, 168, 335 (Day 15 within 1.5 hours before 2nd infusion), 337.5, 339.25 (Day 15 immediately before 2nd infusion end), 408, 504, 672, 1344, and 2016 hours after start of 1st infusion): Maximum Serum Concentration (Cmax) of Rituximab (Predose (Day 1) and 3, 4.25 (immediately before 1st infusion end), 72, 168, 335 (Day 15 within 1.5 hours before 2nd infusion), 337.5, 339.25 (Day 15 immediately before 2nd infusion end), 408, 504, 672, 1344, and 2016 hours after start of 1st infusion): Rituximab-Pfizer 453 micrograms per milliliter (Standard Deviation 153) | Rituximab-EU 422 micrograms per milliliter (Standard Deviation 111) | Rituximab-US 430 micrograms per milliliter (Standard Deviation 163) (met)

Result source: NCT01526057

Rituximab · Rituxan

Marketed by Roche and partners

Approved in Rheumatoid Arthritismonoclonal antibody
Reliable signal

NCT00468546 · Phase 3 · completed

The REFLEX phase 3 trial: randomized, double-blind, placebo-controlled, 520 participants with rheumatoid arthritis who had failed anti-TNF therapy, all on background methotrexate. The primary endpoint, ACR20 response at week 24, was reached by 153 of 298 participants on rituximab (51.3%) versus 36 of 201 on placebo (17.9%). ClinicalTrials.gov records no statistical analysis for the comparison, but a 33-percentage-point difference on a validated clinical response endpoint at this sample size is arithmetically undeniable, so the primary is read as met (significance inferred from counts).

Next expected readout: July 2027 · NCT06581562 (registry estimate)

Reported efficacy

Percentage of Participants With American College of Rheumatology (ACR) 20 Response at Week 24 (Baseline and Week 24): Percentage of Participants With American College of Rheumatology (ACR) 20 Response at Week 24 (Baseline and Week 24): Rituximab 2 x 0.5 g + MTX 54.5% | Rituximab 2 x 1.0 g + MTX 50.6% vs Placebo + MTX 23.3% (met)

Result source: NCT00299130

Results for Rheumatoid Arthritis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointPF-05280586Rituximab
ACR2077.1% vs 90%vs Rituximab-EUwk 25 · n 58NCT01643928
18 other results
  • 81.8% vs 90% wk 25 · n 33 · Phase na · primary NCT01643928
  • 73.7% vs 90% wk 25 · n 30 · Phase na · primary NCT01643928
  • 69.6% vs 77.4% wk 13 · n 58 · Phase na · primary NCT01643928
  • 84.8% vs 77.4% wk 13 · n 33 · Phase na · primary NCT01643928
  • 82.8% vs 77.4% wk 13 · n 30 · Phase na · primary NCT01643928
  • 66.7% vs 71% wk 6 · n 58 · Phase na · primary NCT01643928
  • 84.8% vs 71% wk 6 · n 33 · Phase na · primary NCT01643928
  • 76.7% vs 71% wk 6 · n 30 · Phase na · primary NCT01643928
  • 50% vs 59.4% wk 1 · n 58 · Phase na · primary NCT01643928
  • 63.6% vs 59.4% wk 1 · n 33 · Phase na · primary NCT01643928
  • 60% vs 59.4% wk 1 · n 30 · Phase na · primary NCT01643928
  • 50% vs 60.3% wk 25 · n 73 · Phase 2 · secondary NCT01526057
  • 54.2% vs 62.2% wk 21 · n 73 · Phase 2 · secondary NCT01526057
  • 54.8% vs 67.6% wk 17 · n 73 · Phase 2 · secondary NCT01526057
  • 50.7% vs 70.3% wk 13 · n 73 · Phase 2 · secondary NCT01526057
  • 49.3% vs 60.8% wk 9 · n 73 · Phase 2 · secondary NCT01526057
  • 54.8% vs 56.8% wk 5 · n 73 · Phase 2 · secondary NCT01526057
  • 34.2% vs 33.8% wk 3 · n 73 · Phase 2 · secondary NCT01526057
50.6% vs 23.3%+27.3 vs placebo2 x 1.0 g · wk 24 · n 170NCT00299130
5 other results
  • 54.5% vs 23.3% 2 x 0.5 g · wk 24 · n 167 · Phase 3 · primary NCT00299130
  • 53.5% vs 44.6% wk 48 · n 318 · Phase 3 · primary NCT00266227
  • 51.3% vs 17.9% wk 24 · n 298 · Phase 3 · primary NCT00468546
  • 80% vs 64.3% 1.0 g x 2 · wk 52 · n 250 · Phase 3 · secondary NCT00299104
  • 76.7% vs 64.3% 0.5 g x 2 · wk 52 · n 249 · Phase 3 · secondary NCT00299104
ACR5051.4% vs 30%vs Rituximab-EUwk 25 · n 58NCT01643928
18 other results
  • 63.6% vs 30% wk 25 · n 33 · Phase na · primary NCT01643928
  • 36.8% vs 30% wk 25 · n 30 · Phase na · primary NCT01643928
  • 37.5% vs 41.9% wk 13 · n 58 · Phase na · primary NCT01643928
  • 66.7% vs 41.9% wk 13 · n 33 · Phase na · primary NCT01643928
  • 58.6% vs 41.9% wk 13 · n 30 · Phase na · primary NCT01643928
  • 33.3% vs 51.6% wk 6 · n 58 · Phase na · primary NCT01643928
  • 51.5% vs 51.6% wk 6 · n 33 · Phase na · primary NCT01643928
  • 53.3% vs 51.6% wk 6 · n 30 · Phase na · primary NCT01643928
  • 17.2% vs 28.1% wk 1 · n 58 · Phase na · primary NCT01643928
  • 48.5% vs 28.1% wk 1 · n 33 · Phase na · primary NCT01643928
  • 30% vs 28.1% wk 1 · n 30 · Phase na · primary NCT01643928
  • 21% vs 38.1% wk 25 · n 73 · Phase 2 · secondary NCT01526057
  • 27.8% vs 37.8% wk 21 · n 73 · Phase 2 · secondary NCT01526057
  • 24.7% vs 36.5% wk 17 · n 73 · Phase 2 · secondary NCT01526057
  • 35.6% vs 40.5% wk 13 · n 73 · Phase 2 · secondary NCT01526057
  • 21.9% vs 32.4% wk 9 · n 73 · Phase 2 · secondary NCT01526057
  • 19.2% vs 16.2% wk 5 · n 73 · Phase 2 · secondary NCT01526057
  • 8.2% vs 5.4% wk 3 · n 73 · Phase 2 · secondary NCT01526057
64.8% vs 41.8%+23 vs placebo1.0 g x 2 · wk 52 · n 250NCT00299104
6 other results
  • 34.1% vs 18.6% 2 x 1.0 g · wk 48 · n 170 · Phase 3 · secondary NCT00299130
  • 25.9% vs 9.3% 2 x 1.0 g · wk 24 · n 170 · Phase 3 · secondary NCT00299130
  • 59.4% vs 41.8% 0.5 g x 2 · wk 52 · n 249 · Phase 3 · secondary NCT00299104
  • 32.9% vs 18.6% 2 x 0.5 g · wk 48 · n 167 · Phase 3 · secondary NCT00299130
  • 26.3% vs 9.3% 2 x 0.5 g · wk 24 · n 167 · Phase 3 · secondary NCT00299130
  • 26.8% vs 5.5% wk 24 · n 298 · Phase 3 · secondary NCT00468546
ACR7022.9% vs 10%vs Rituximab-EUwk 25 · n 58NCT01643928
18 other results
  • 36.4% vs 10% wk 25 · n 33 · Phase na · primary NCT01643928
  • 15.8% vs 10% wk 25 · n 30 · Phase na · primary NCT01643928
  • 23.2% vs 32.3% wk 13 · n 58 · Phase na · primary NCT01643928
  • 36.4% vs 32.3% wk 13 · n 33 · Phase na · primary NCT01643928
  • 34.5% vs 32.3% wk 13 · n 30 · Phase na · primary NCT01643928
  • 21.1% vs 22.6% wk 6 · n 58 · Phase na · primary NCT01643928
  • 33.3% vs 22.6% wk 6 · n 33 · Phase na · primary NCT01643928
  • 30% vs 22.6% wk 6 · n 30 · Phase na · primary NCT01643928
  • 5.2% vs 12.5% wk 1 · n 58 · Phase na · primary NCT01643928
  • 21.2% vs 12.5% wk 1 · n 33 · Phase na · primary NCT01643928
  • 10% vs 12.5% wk 1 · n 30 · Phase na · primary NCT01643928
  • 16.1% vs 17.5% wk 25 · n 73 · Phase 2 · secondary NCT01526057
  • 13.9% vs 23% wk 21 · n 73 · Phase 2 · secondary NCT01526057
  • 15.1% vs 18.9% wk 17 · n 73 · Phase 2 · secondary NCT01526057
  • 19.2% vs 28.4% wk 13 · n 73 · Phase 2 · secondary NCT01526057
  • 12.3% vs 17.6% wk 9 · n 73 · Phase 2 · secondary NCT01526057
  • 6.8% vs 6.8% wk 5 · n 73 · Phase 2 · secondary NCT01526057
  • 2.7% vs 2.7% wk 3 · n 73 · Phase 2 · secondary NCT01526057
46.8% vs 24.9%+21.9 vs placebo1.0 g x 2 · wk 52 · n 250NCT00299104
6 other results
  • 13.5% vs 9.3% 2 x 1.0 g · wk 48 · n 170 · Phase 3 · secondary NCT00299130
  • 10% vs 5.2% 2 x 1.0 g · wk 24 · n 170 · Phase 3 · secondary NCT00299130
  • 42.2% vs 24.9% 0.5 g x 2 · wk 52 · n 249 · Phase 3 · secondary NCT00299104
  • 12.6% vs 9.3% 2 x 0.5 g · wk 48 · n 167 · Phase 3 · secondary NCT00299130
  • 9% vs 5.2% 2 x 0.5 g · wk 24 · n 167 · Phase 3 · secondary NCT00299130
  • 12.4% vs 1.5% wk 24 · n 298 · Phase 3 · secondary NCT00468546
DAS28-CRP remission45.7% vs 20%vs Rituximab-EUwk 25 · n 58NCT01643928
11 other results
  • 27.3% vs 20% wk 25 · n 33 · Phase na · primary NCT01643928
  • 21.1% vs 20% wk 25 · n 30 · Phase na · primary NCT01643928
  • 33.9% vs 46.7% wk 13 · n 58 · Phase na · primary NCT01643928
  • 45.5% vs 46.7% wk 13 · n 33 · Phase na · primary NCT01643928
  • 37.9% vs 46.7% wk 13 · n 30 · Phase na · primary NCT01643928
  • 32.1% vs 38.7% wk 6 · n 58 · Phase na · primary NCT01643928
  • 34.4% vs 38.7% wk 6 · n 33 · Phase na · primary NCT01643928
  • 32.1% vs 38.7% wk 6 · n 30 · Phase na · primary NCT01643928
  • 3.9% vs 10.7% wk 1 · n 58 · Phase na · primary NCT01643928
  • 19.4% vs 10.7% wk 1 · n 33 · Phase na · primary NCT01643928
  • 7.1% vs 10.7% wk 1 · n 30 · Phase na · primary NCT01643928
—Not posted · NCT00578305
HAQ-DI, change-0.4 vs -0.5vs Rituximabwk 25 · n 73NCT01526057
6 other results
  • -0.4 vs -0.6 wk 21 · n 73 · Phase 2 · secondary NCT01526057
  • -0.3 vs -0.6 wk 17 · n 73 · Phase 2 · secondary NCT01526057
  • -0.4 vs -0.6 wk 13 · n 73 · Phase 2 · secondary NCT01526057
  • -0.4 vs -0.5 wk 9 · n 73 · Phase 2 · secondary NCT01526057
  • -0.3 vs -0.3 wk 5 · n 73 · Phase 2 · secondary NCT01526057
  • -0.2 vs -0.2 wk 3 · n 73 · Phase 2 · secondary NCT01526057
-1.1 vs -0.8−0.2 vs placebo1.0 g x 2 · wk 104 · n 248NCT00299104
9 other results
  • -1.0 vs -0.8 1.0 g x 2 · wk 52 · n 249 · Phase 3 · secondary NCT00299104
  • -1038 vs -0.8 0.5 g x 2 · wk 104 · n 247 · Phase 3 · secondary NCT00299104
  • -1.0 vs -0.8 0.5 g x 2 · wk 52 · n 247 · Phase 3 · secondary NCT00299104
  • -0.3 vs -0.2 wk 48 · n 316 · Phase 3 · secondary NCT00266227
  • -0.4 vs -0.2 1000 mg · wk 52 · n 60 · Phase 3 · secondary NCT00578305
  • -0.4 vs -0.2 1000 mg · wk 24 · n 60 · Phase 3 · secondary NCT00578305
  • -0.5 vs -0.2 500 mg · wk 52 · n 62 · Phase 3 · secondary NCT00578305
  • -0.4 vs -0.2 500 mg · wk 24 · n 62 · Phase 3 · secondary NCT00578305
  • -0.5 vs -0.4 wk 260 · n 100 · Phase 3 · secondary NCT02097745
Modified Sharp score, change—Not reported0.4 vs 1.1−0.7 vs placebo1.0 g x 2 · wk 52 · n 244NCT00299104
6 other results
  • 0.6 vs 1.1 0.5 g x 2 · wk 52 · n 239 · Phase 3 · primary NCT00299104
  • 0.4 vs 1.9 1.0 g x 2 · wk 104 · n 243 · Phase 3 · secondary NCT00299104
  • 0.3 vs 0.7 1.0 g x 2 · wk 24 · n 242 · Phase 3 · secondary NCT00299104
  • 0.8 vs 1.9 0.5 g x 2 · wk 104 · n 238 · Phase 3 · secondary NCT00299104
  • 0.5 vs 0.7 0.5 g x 2 · wk 24 · n 238 · Phase 3 · secondary NCT00299104
  • 3.2 vs 5.4 wk 260 · n 105 · Phase 3 · secondary NCT02097745

ACR20

PF-05280586
77.1% vs 90%vs Rituximab-EUwk 25 · n 58NCT01643928
18 other results
  • 81.8% vs 90% wk 25 · n 33 · Phase na · primary NCT01643928
  • 73.7% vs 90% wk 25 · n 30 · Phase na · primary NCT01643928
  • 69.6% vs 77.4% wk 13 · n 58 · Phase na · primary NCT01643928
  • 84.8% vs 77.4% wk 13 · n 33 · Phase na · primary NCT01643928
  • 82.8% vs 77.4% wk 13 · n 30 · Phase na · primary NCT01643928
  • 66.7% vs 71% wk 6 · n 58 · Phase na · primary NCT01643928
  • 84.8% vs 71% wk 6 · n 33 · Phase na · primary NCT01643928
  • 76.7% vs 71% wk 6 · n 30 · Phase na · primary NCT01643928
  • 50% vs 59.4% wk 1 · n 58 · Phase na · primary NCT01643928
  • 63.6% vs 59.4% wk 1 · n 33 · Phase na · primary NCT01643928
  • 60% vs 59.4% wk 1 · n 30 · Phase na · primary NCT01643928
  • 50% vs 60.3% wk 25 · n 73 · Phase 2 · secondary NCT01526057
  • 54.2% vs 62.2% wk 21 · n 73 · Phase 2 · secondary NCT01526057
  • 54.8% vs 67.6% wk 17 · n 73 · Phase 2 · secondary NCT01526057
  • 50.7% vs 70.3% wk 13 · n 73 · Phase 2 · secondary NCT01526057
  • 49.3% vs 60.8% wk 9 · n 73 · Phase 2 · secondary NCT01526057
  • 54.8% vs 56.8% wk 5 · n 73 · Phase 2 · secondary NCT01526057
  • 34.2% vs 33.8% wk 3 · n 73 · Phase 2 · secondary NCT01526057
Rituximab
50.6% vs 23.3%+27.3 vs placebo2 x 1.0 g · wk 24 · n 170NCT00299130
5 other results
  • 54.5% vs 23.3% 2 x 0.5 g · wk 24 · n 167 · Phase 3 · primary NCT00299130
  • 53.5% vs 44.6% wk 48 · n 318 · Phase 3 · primary NCT00266227
  • 51.3% vs 17.9% wk 24 · n 298 · Phase 3 · primary NCT00468546
  • 80% vs 64.3% 1.0 g x 2 · wk 52 · n 250 · Phase 3 · secondary NCT00299104
  • 76.7% vs 64.3% 0.5 g x 2 · wk 52 · n 249 · Phase 3 · secondary NCT00299104

ACR50

PF-05280586
51.4% vs 30%vs Rituximab-EUwk 25 · n 58NCT01643928
18 other results
  • 63.6% vs 30% wk 25 · n 33 · Phase na · primary NCT01643928
  • 36.8% vs 30% wk 25 · n 30 · Phase na · primary NCT01643928
  • 37.5% vs 41.9% wk 13 · n 58 · Phase na · primary NCT01643928
  • 66.7% vs 41.9% wk 13 · n 33 · Phase na · primary NCT01643928
  • 58.6% vs 41.9% wk 13 · n 30 · Phase na · primary NCT01643928
  • 33.3% vs 51.6% wk 6 · n 58 · Phase na · primary NCT01643928
  • 51.5% vs 51.6% wk 6 · n 33 · Phase na · primary NCT01643928
  • 53.3% vs 51.6% wk 6 · n 30 · Phase na · primary NCT01643928
  • 17.2% vs 28.1% wk 1 · n 58 · Phase na · primary NCT01643928
  • 48.5% vs 28.1% wk 1 · n 33 · Phase na · primary NCT01643928
  • 30% vs 28.1% wk 1 · n 30 · Phase na · primary NCT01643928
  • 21% vs 38.1% wk 25 · n 73 · Phase 2 · secondary NCT01526057
  • 27.8% vs 37.8% wk 21 · n 73 · Phase 2 · secondary NCT01526057
  • 24.7% vs 36.5% wk 17 · n 73 · Phase 2 · secondary NCT01526057
  • 35.6% vs 40.5% wk 13 · n 73 · Phase 2 · secondary NCT01526057
  • 21.9% vs 32.4% wk 9 · n 73 · Phase 2 · secondary NCT01526057
  • 19.2% vs 16.2% wk 5 · n 73 · Phase 2 · secondary NCT01526057
  • 8.2% vs 5.4% wk 3 · n 73 · Phase 2 · secondary NCT01526057
Rituximab
64.8% vs 41.8%+23 vs placebo1.0 g x 2 · wk 52 · n 250NCT00299104
6 other results
  • 34.1% vs 18.6% 2 x 1.0 g · wk 48 · n 170 · Phase 3 · secondary NCT00299130
  • 25.9% vs 9.3% 2 x 1.0 g · wk 24 · n 170 · Phase 3 · secondary NCT00299130
  • 59.4% vs 41.8% 0.5 g x 2 · wk 52 · n 249 · Phase 3 · secondary NCT00299104
  • 32.9% vs 18.6% 2 x 0.5 g · wk 48 · n 167 · Phase 3 · secondary NCT00299130
  • 26.3% vs 9.3% 2 x 0.5 g · wk 24 · n 167 · Phase 3 · secondary NCT00299130
  • 26.8% vs 5.5% wk 24 · n 298 · Phase 3 · secondary NCT00468546

ACR70

PF-05280586
22.9% vs 10%vs Rituximab-EUwk 25 · n 58NCT01643928
18 other results
  • 36.4% vs 10% wk 25 · n 33 · Phase na · primary NCT01643928
  • 15.8% vs 10% wk 25 · n 30 · Phase na · primary NCT01643928
  • 23.2% vs 32.3% wk 13 · n 58 · Phase na · primary NCT01643928
  • 36.4% vs 32.3% wk 13 · n 33 · Phase na · primary NCT01643928
  • 34.5% vs 32.3% wk 13 · n 30 · Phase na · primary NCT01643928
  • 21.1% vs 22.6% wk 6 · n 58 · Phase na · primary NCT01643928
  • 33.3% vs 22.6% wk 6 · n 33 · Phase na · primary NCT01643928
  • 30% vs 22.6% wk 6 · n 30 · Phase na · primary NCT01643928
  • 5.2% vs 12.5% wk 1 · n 58 · Phase na · primary NCT01643928
  • 21.2% vs 12.5% wk 1 · n 33 · Phase na · primary NCT01643928
  • 10% vs 12.5% wk 1 · n 30 · Phase na · primary NCT01643928
  • 16.1% vs 17.5% wk 25 · n 73 · Phase 2 · secondary NCT01526057
  • 13.9% vs 23% wk 21 · n 73 · Phase 2 · secondary NCT01526057
  • 15.1% vs 18.9% wk 17 · n 73 · Phase 2 · secondary NCT01526057
  • 19.2% vs 28.4% wk 13 · n 73 · Phase 2 · secondary NCT01526057
  • 12.3% vs 17.6% wk 9 · n 73 · Phase 2 · secondary NCT01526057
  • 6.8% vs 6.8% wk 5 · n 73 · Phase 2 · secondary NCT01526057
  • 2.7% vs 2.7% wk 3 · n 73 · Phase 2 · secondary NCT01526057
Rituximab
46.8% vs 24.9%+21.9 vs placebo1.0 g x 2 · wk 52 · n 250NCT00299104
6 other results
  • 13.5% vs 9.3% 2 x 1.0 g · wk 48 · n 170 · Phase 3 · secondary NCT00299130
  • 10% vs 5.2% 2 x 1.0 g · wk 24 · n 170 · Phase 3 · secondary NCT00299130
  • 42.2% vs 24.9% 0.5 g x 2 · wk 52 · n 249 · Phase 3 · secondary NCT00299104
  • 12.6% vs 9.3% 2 x 0.5 g · wk 48 · n 167 · Phase 3 · secondary NCT00299130
  • 9% vs 5.2% 2 x 0.5 g · wk 24 · n 167 · Phase 3 · secondary NCT00299130
  • 12.4% vs 1.5% wk 24 · n 298 · Phase 3 · secondary NCT00468546

DAS28-CRP remission

PF-05280586
45.7% vs 20%vs Rituximab-EUwk 25 · n 58NCT01643928
11 other results
  • 27.3% vs 20% wk 25 · n 33 · Phase na · primary NCT01643928
  • 21.1% vs 20% wk 25 · n 30 · Phase na · primary NCT01643928
  • 33.9% vs 46.7% wk 13 · n 58 · Phase na · primary NCT01643928
  • 45.5% vs 46.7% wk 13 · n 33 · Phase na · primary NCT01643928
  • 37.9% vs 46.7% wk 13 · n 30 · Phase na · primary NCT01643928
  • 32.1% vs 38.7% wk 6 · n 58 · Phase na · primary NCT01643928
  • 34.4% vs 38.7% wk 6 · n 33 · Phase na · primary NCT01643928
  • 32.1% vs 38.7% wk 6 · n 30 · Phase na · primary NCT01643928
  • 3.9% vs 10.7% wk 1 · n 58 · Phase na · primary NCT01643928
  • 19.4% vs 10.7% wk 1 · n 33 · Phase na · primary NCT01643928
  • 7.1% vs 10.7% wk 1 · n 30 · Phase na · primary NCT01643928
Rituximab
—Not posted · NCT00578305

HAQ-DI, change

PF-05280586
-0.4 vs -0.5vs Rituximabwk 25 · n 73NCT01526057
6 other results
  • -0.4 vs -0.6 wk 21 · n 73 · Phase 2 · secondary NCT01526057
  • -0.3 vs -0.6 wk 17 · n 73 · Phase 2 · secondary NCT01526057
  • -0.4 vs -0.6 wk 13 · n 73 · Phase 2 · secondary NCT01526057
  • -0.4 vs -0.5 wk 9 · n 73 · Phase 2 · secondary NCT01526057
  • -0.3 vs -0.3 wk 5 · n 73 · Phase 2 · secondary NCT01526057
  • -0.2 vs -0.2 wk 3 · n 73 · Phase 2 · secondary NCT01526057
Rituximab
-1.1 vs -0.8−0.2 vs placebo1.0 g x 2 · wk 104 · n 248NCT00299104
9 other results
  • -1.0 vs -0.8 1.0 g x 2 · wk 52 · n 249 · Phase 3 · secondary NCT00299104
  • -1038 vs -0.8 0.5 g x 2 · wk 104 · n 247 · Phase 3 · secondary NCT00299104
  • -1.0 vs -0.8 0.5 g x 2 · wk 52 · n 247 · Phase 3 · secondary NCT00299104
  • -0.3 vs -0.2 wk 48 · n 316 · Phase 3 · secondary NCT00266227
  • -0.4 vs -0.2 1000 mg · wk 52 · n 60 · Phase 3 · secondary NCT00578305
  • -0.4 vs -0.2 1000 mg · wk 24 · n 60 · Phase 3 · secondary NCT00578305
  • -0.5 vs -0.2 500 mg · wk 52 · n 62 · Phase 3 · secondary NCT00578305
  • -0.4 vs -0.2 500 mg · wk 24 · n 62 · Phase 3 · secondary NCT00578305
  • -0.5 vs -0.4 wk 260 · n 100 · Phase 3 · secondary NCT02097745

Modified Sharp score, change

PF-05280586
—Not reported
Rituximab
0.4 vs 1.1−0.7 vs placebo1.0 g x 2 · wk 52 · n 244NCT00299104
6 other results
  • 0.6 vs 1.1 0.5 g x 2 · wk 52 · n 239 · Phase 3 · primary NCT00299104
  • 0.4 vs 1.9 1.0 g x 2 · wk 104 · n 243 · Phase 3 · secondary NCT00299104
  • 0.3 vs 0.7 1.0 g x 2 · wk 24 · n 242 · Phase 3 · secondary NCT00299104
  • 0.8 vs 1.9 0.5 g x 2 · wk 104 · n 238 · Phase 3 · secondary NCT00299104
  • 0.5 vs 0.7 0.5 g x 2 · wk 24 · n 238 · Phase 3 · secondary NCT00299104
  • 3.2 vs 5.4 wk 260 · n 105 · Phase 3 · secondary NCT02097745
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
13 other shared endpoints and safety

Coverage. PF-05280586: 17 of 17 rows · Rituximab: 17 of 17 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricPF-05280586
Rows use multiple source trials
Rituximab
Rows use multiple source trials
DAS Low Disease Activity
responder rate · % of participants
32% (n=73) vs 37.9% (n=74) Rituximab @ 25wka,b,c,d
NCT01526057 · Phase 2 · Rheumatoid Arthritis · phase 2
43% (n=249) vs 19.8% (n=247) placebo @ 52wk1.0 g x 2e,a,b,c,d
NCT00299104 · Phase 3 · combination
show 1 more dose
40.3% (n=248) vs 19.8% (n=247) placebo @ 52wk0.5 g x 2
NCT00299104 · Phase 3 · combination
DAS28-CRP
absolute change · score
-1.7 vs -2 Rituximab score @ 25wka,b,c,f
NCT01526057 · Phase 2 · Rheumatoid Arthritis · phase 2
-1.8 vs -1.5 placebo score @ 48wka,b,c,f
NCT00266227 · Phase 3
EULAR Good
responder rate · % of participants
30% (n=73) vs 36.2% (n=74) Rituximab @ 25wka,b,c,d
NCT01526057 · Phase 2 · Rheumatoid Arthritis · phase 2
3 other source trials
36.4% (n=33) vs 20% (n=32) Rituximab-EU @ 25wk
NCT01643928 · Phase na · registry result, not featured evidence
36.8% (n=30) vs 20% (n=32) Rituximab-EU @ 25wk
NCT01643928 · Phase na · registry result, not featured evidence
57.1% (n=58) vs 20% (n=32) Rituximab-EU @ 25wk
NCT01643928 · Phase na · registry result, not featured evidence
41.6% (n=250) vs 18.1% (n=249) placebo @ 52wk1.0 g x 2e,a,b,c,d
NCT00299104 · Phase 3 · combination
show 1 more dose
39% (n=249) vs 18.1% (n=249) placebo @ 52wk0.5 g x 2
NCT00299104 · Phase 3 · combination
HAQ-DI
percent change · % of baseline
-43.6% (n=33) vs -24.1% (n=32) Rituximab-EU @ 25wke,g,b,c,f
NCT01643928 · Phase na · registry result, not featured evidence
show 2 more doses
-27.2% (n=30) vs -24.1% (n=32) Rituximab-EU @ 25wk
NCT01643928 · Phase na · registry result, not featured evidence
-26.3% (n=58) vs -24.1% (n=32) Rituximab-EU @ 25wk
NCT01643928 · Phase na · registry result, not featured evidence
-30.6% (n=170) vs -22.6% (n=172) placebo @ 48wk2 x 1.0 ge,g,b,c,f
NCT00299130 · Phase 3 · combination
show 1 more dose
-30.2% (n=167) vs -22.6% (n=172) placebo @ 48wk2 x 0.5 g
NCT00299130 · Phase 3 · combination
Patient Assessment of Arthritis Pain
percent change · % of baseline
-52.5% (n=33) vs -19.6% (n=32) Rituximab-EU @ 25wke,g,b,c,f
NCT01643928 · Phase na · registry result, not featured evidence
show 2 more doses
-45.4% (n=30) vs -19.6% (n=32) Rituximab-EU @ 25wk
NCT01643928 · Phase na · registry result, not featured evidence
-49.7% (n=58) vs -19.6% (n=32) Rituximab-EU @ 25wk
NCT01643928 · Phase na · registry result, not featured evidence
-36.3% (n=170) vs -24.4% (n=172) placebo @ 48wk2 x 1.0 ge,g,b,c,f
NCT00299130 · Phase 3 · combination
show 1 more dose
-35.5% (n=167) vs -24.4% (n=172) placebo @ 48wk2 x 0.5 g
NCT00299130 · Phase 3 · combination
Patient Global Assessment
percent change · % of baseline
-48.4% (n=33) vs -42.3% (n=32) Rituximab-EU @ 25wke,g,b,c,f
NCT01643928 · Phase na · registry result, not featured evidence
show 2 more doses
-46.5% (n=30) vs -42.3% (n=32) Rituximab-EU @ 25wk
NCT01643928 · Phase na · registry result, not featured evidence
-52.6% (n=58) vs -42.3% (n=32) Rituximab-EU @ 25wk
NCT01643928 · Phase na · registry result, not featured evidence
-36.6% (n=170) vs -28% (n=172) placebo @ 48wk2 x 1.0 ge,g,b,c,f
NCT00299130 · Phase 3 · combination
show 1 more dose
-39.7% (n=167) vs -28% (n=172) placebo @ 48wk2 x 0.5 g
NCT00299130 · Phase 3 · combination
Physician Global Assessment
percent change · % of baseline
-71.4% (n=33) vs -73.2% (n=32) Rituximab-EU @ 25wke,g,b,c,f
NCT01643928 · Phase na · registry result, not featured evidence
show 2 more doses
-59.9% (n=30) vs -73.2% (n=32) Rituximab-EU @ 25wk
NCT01643928 · Phase na · registry result, not featured evidence
-67% (n=58) vs -73.2% (n=32) Rituximab-EU @ 25wk
NCT01643928 · Phase na · registry result, not featured evidence
-49% (n=170) vs -39.4% (n=172) placebo @ 48wk2 x 1.0 ge,g,b,c,f
NCT00299130 · Phase 3 · combination
show 1 more dose
-40.5% (n=167) vs -39.4% (n=172) placebo @ 48wk2 x 0.5 g
NCT00299130 · Phase 3 · combination
SJC
percent change · % of baseline
No placebo or comparator arm
Change at Course 1/Week 13
-77.8% (n=31) @ 13wke,b,c
NCT01643928 · Phase na · registry result, not featured evidence
show 5 more doses
-77% (n=30) @ 13wk
NCT01643928 · Phase na · registry result, not featured evidence
-70% (n=29) @ 13wk
NCT01643928 · Phase na · registry result, not featured evidence
-70% (n=29) @ 13wk
NCT01643928 · Phase na · registry result, not featured evidence
-78.3% (n=54) @ 13wk
NCT01643928 · Phase na · registry result, not featured evidence
-79.3% (n=48) @ 13wk
NCT01643928 · Phase na · registry result, not featured evidence
-47.2% (n=32) @ 13wke,b,c
NCT01643928 · Phase na · registry result, not featured evidence
show 1 more dose
-79.5% (n=30) @ 13wk
NCT01643928 · Phase na · registry result, not featured evidence
SJC
percent change · % of baseline
No placebo or comparator arm
Change at Course 1/Week 25
-76% (n=31) @ 25wke,b,c
NCT01643928 · Phase na · registry result, not featured evidence
show 5 more doses
-74.8% (n=30) @ 25wk
NCT01643928 · Phase na · registry result, not featured evidence
-67.2% (n=29) @ 25wk
NCT01643928 · Phase na · registry result, not featured evidence
-67.2% (n=29) @ 25wk
NCT01643928 · Phase na · registry result, not featured evidence
-75% (n=54) @ 25wk
NCT01643928 · Phase na · registry result, not featured evidence
-73.5% (n=48) @ 25wk
NCT01643928 · Phase na · registry result, not featured evidence
-74.1% (n=32) @ 25wke,b,c
NCT01643928 · Phase na · registry result, not featured evidence
show 1 more dose
-58.6% (n=30) @ 25wk
NCT01643928 · Phase na · registry result, not featured evidence
SJC
percent change · % of baseline
No placebo or comparator arm
Change at Course 1/Week 6
-72.5% (n=31) @ 6wke,b,c
NCT01643928 · Phase na · registry result, not featured evidence
show 5 more doses
-71.5% (n=30) @ 6wk
NCT01643928 · Phase na · registry result, not featured evidence
-78.2% (n=29) @ 6wk
NCT01643928 · Phase na · registry result, not featured evidence
-78.2% (n=29) @ 6wk
NCT01643928 · Phase na · registry result, not featured evidence
-62.7% (n=54) @ 6wk
NCT01643928 · Phase na · registry result, not featured evidence
-62.1% (n=48) @ 6wk
NCT01643928 · Phase na · registry result, not featured evidence
-55.1% (n=32) @ 6wke,b,c
NCT01643928 · Phase na · registry result, not featured evidence
show 1 more dose
-68.2% (n=30) @ 6wk
NCT01643928 · Phase na · registry result, not featured evidence
TJC
percent change · % of baseline
No placebo or comparator arm
Change at Course 1/Week 13
-73.7% (n=30) @ 13wke,b,c
NCT01643928 · Phase na · registry result, not featured evidence
show 2 more doses
-68.7% (n=29) @ 13wk
NCT01643928 · Phase na · registry result, not featured evidence
-75.1% (n=48) @ 13wk
NCT01643928 · Phase na · registry result, not featured evidence
-76.6% (n=32) @ 13wke,b,c
NCT01643928 · Phase na · registry result, not featured evidence
show 1 more dose
-70.6% (n=30) @ 13wk
NCT01643928 · Phase na · registry result, not featured evidence
TJC
percent change · % of baseline
No placebo or comparator arm
Change at Course 1/Week 25
-68.8% (n=30) @ 25wke,b,c
NCT01643928 · Phase na · registry result, not featured evidence
show 2 more doses
-69.9% (n=29) @ 25wk
NCT01643928 · Phase na · registry result, not featured evidence
-69% (n=48) @ 25wk
NCT01643928 · Phase na · registry result, not featured evidence
-57.1% (n=32) @ 25wke,b,c
NCT01643928 · Phase na · registry result, not featured evidence
show 1 more dose
-57% (n=30) @ 25wk
NCT01643928 · Phase na · registry result, not featured evidence
TJC
percent change · % of baseline
No placebo or comparator arm
Change at Course 1/Week 6
-73.3% (n=30) @ 6wke,b,c
NCT01643928 · Phase na · registry result, not featured evidence
show 2 more doses
-70.5% (n=29) @ 6wk
NCT01643928 · Phase na · registry result, not featured evidence
-53.6% (n=48) @ 6wk
NCT01643928 · Phase na · registry result, not featured evidence
-72.1% (n=32) @ 6wke,b,c
NCT01643928 · Phase na · registry result, not featured evidence
show 1 more dose
-68.7% (n=30) @ 6wk
NCT01643928 · Phase na · registry result, not featured evidence
Dropout rate
12.3%h
NCT01526057 · Phase 2 · Rheumatoid Arthritis · phase 2
show 12 more results
—PF-05280586 (EU): by the End of Co
NCT01643928 · Phase na · registry result, not featured evidence
—PF-05280586 (EU): by the End of Co
NCT01643928 · Phase na · registry result, not featured evidence
—PF-05280586 (EU): by the End of Co
NCT01643928 · Phase na · registry result, not featured evidence
—PF-05280586 (US): by the End of Co
NCT01643928 · Phase na · registry result, not featured evidence
—PF-05280586 (US): by the End of Co
NCT01643928 · Phase na · registry result, not featured evidence
—PF-05280586 (US): by the End of Co
NCT01643928 · Phase na · registry result, not featured evidence
17.2%PF-05280586/PF-05280586/PF-0528058
NCT01643928 · Phase na · registry result, not featured evidence
9.1%PF-05280586/PF-05280586/PF-0528058
NCT01643928 · Phase na · registry result, not featured evidence
6.7%PF-05280586/PF-05280586/PF-0528058
NCT01643928 · Phase na · registry result, not featured evidence
—PF-05280586: by the End of Course
NCT01643928 · Phase na · registry result, not featured evidence
—PF-05280586: by the End of Course
NCT01643928 · Phase na · registry result, not featured evidence
—PF-05280586: by the End of Course
NCT01643928 · Phase na · registry result, not featured evidence
17.9%i
NCT00468546 · Phase 3 · combination
show 48 more results
—
NCT00266227 · Phase 3
68.3%1.0 g x 2
NCT00299104 · Phase 3 · combination
69.4%0.5 g x 2
NCT00299104 · Phase 3 · combination
—1.0 g
NCT00299130 · Phase 3 · combination
29.2%2 x 1.0 g
NCT00299130 · Phase 3 · combination
25.6%2 x 0.5 g
NCT00299130 · Phase 3 · combination
20.8%
NCT01382940 · Phase 4 · registry result, not featured evidence
33.3%
NCT01000610 · Phase 4 · registry result, not featured evidence
—1000 mg
NCT00934648 · Phase 4 · registry result, not featured evidence
—
NCT00502853 · Phase 4 · registry result, not featured evidence · combination
—
NCT00504777 · Phase 4 · registry result, not featured evidence · combination
—1000 mg
NCT00424502 · Phase 4 · registry result, not featured evidence
7.5%
NCT00462345 · Phase 4 · registry result, not featured evidence · combination
53.1%
NCT02097745 · Phase 3 · registry result, not featured evidence
25.1%
NCT00503425 · Phase 3 · registry result, not featured evidence
6.7%1000 mg
NCT00578305 · Phase 3 · registry result, not featured evidence
—1000 mg
NCT00578305 · Phase 3 · registry result, not featured evidence
—1000 mg
NCT00578305 · Phase 3 · registry result, not featured evidence
—1000 mg
NCT00578305 · Phase 3 · registry result, not featured evidence
4.8%500 mg
NCT00578305 · Phase 3 · registry result, not featured evidence
—500 mg
NCT00578305 · Phase 3 · registry result, not featured evidence
—500 mg
NCT00578305 · Phase 3 · registry result, not featured evidence
—500 mg
NCT00578305 · Phase 3 · registry result, not featured evidence
12%Decreased Dose
NCT00422383 · Phase 3 · registry result, not featured evidence · combination
11.7%Escalated Dose
NCT00422383 · Phase 3 · registry result, not featured evidence · combination
4.3%High Dose
NCT00422383 · Phase 3 · registry result, not featured evidence · combination
—Low Dose
NCT00422383 · Phase 3 · registry result, not featured evidence · combination
23.7%1000 mg
NCT00443651 · Phase 3 · registry result, not featured evidence
33%500 mg
NCT00443651 · Phase 3 · registry result, not featured evidence
32.1%1000 mg
NCT01126541 · Phase 3 · registry result, not featured evidence
—1000 mg
NCT01126541 · Phase 3 · registry result, not featured evidence
16.4%1000 mg x 2
NCT01126541 · Phase 3 · registry result, not featured evidence
—
NCT00502840 · Phase 3 · registry result, not featured evidence · background therapy
30%
NCT00578565 · Phase 3 · registry result, not featured evidence
—
NCT02079532 · Phase 3 · registry result, not featured evidence · combination
—Initial Treatment: Rituximab + MTX
NCT01272908 · Phase 3 · registry result, not featured evidence · combination
—Re-treatment: Rituximab + MTX
NCT01272908 · Phase 3 · registry result, not featured evidence · combination
19%
NCT00502996 · Phase 3 · registry result, not featured evidence
—
NCT02006706 · Phase 3 · registry result, not featured evidence · combination
41.5%
NCT02093026 · Phase 2 · registry result, not featured evidence
5.8%Rituximab + Methotrexate (Group A)
NCT00282308 · Phase 2 · registry result, not featured evidence · combination
—Rituximab + Methotrexate (Group A)
NCT00282308 · Phase 2 · registry result, not featured evidence · combination
0%
NCT00147966 · Phase 2 · registry result, not featured evidence
52.4%1000 mg
NCT00243412 · Phase 2 · registry result, not featured evidence
47.6%500 mg
NCT00243412 · Phase 2 · registry result, not featured evidence
—Rituximab-EU: by the End of Course
NCT01643928 · Phase na · registry result, not featured evidence
—Rituximab-US: by the End of Course
NCT01643928 · Phase na · registry result, not featured evidence
0%
NCT00844714 · Phase na · registry result, not featured evidence
Discontinued due to AEs
4.1%h
NCT01526057 · Phase 2 · Rheumatoid Arthritis · phase 2
show 12 more results
—PF-05280586 (EU): by the End of Co
NCT01643928 · Phase na · registry result, not featured evidence
—PF-05280586 (EU): by the End of Co
NCT01643928 · Phase na · registry result, not featured evidence
—PF-05280586 (EU): by the End of Co
NCT01643928 · Phase na · registry result, not featured evidence
—PF-05280586 (US): by the End of Co
NCT01643928 · Phase na · registry result, not featured evidence
—PF-05280586 (US): by the End of Co
NCT01643928 · Phase na · registry result, not featured evidence
—PF-05280586 (US): by the End of Co
NCT01643928 · Phase na · registry result, not featured evidence
3.4%PF-05280586/PF-05280586/PF-0528058
NCT01643928 · Phase na · registry result, not featured evidence
0%PF-05280586/PF-05280586/PF-0528058
NCT01643928 · Phase na · registry result, not featured evidence
6.7%PF-05280586/PF-05280586/PF-0528058
NCT01643928 · Phase na · registry result, not featured evidence
—PF-05280586: by the End of Course
NCT01643928 · Phase na · registry result, not featured evidence
—PF-05280586: by the End of Course
NCT01643928 · Phase na · registry result, not featured evidence
—PF-05280586: by the End of Course
NCT01643928 · Phase na · registry result, not featured evidence
2.6%i
NCT00468546 · Phase 3 · combination
show 48 more results
—
NCT00266227 · Phase 3
2.8%1.0 g x 2
NCT00299104 · Phase 3 · combination
3.6%0.5 g x 2
NCT00299104 · Phase 3 · combination
—1.0 g
NCT00299130 · Phase 3 · combination
7.6%2 x 1.0 g
NCT00299130 · Phase 3 · combination
4.8%2 x 0.5 g
NCT00299130 · Phase 3 · combination
5.4%
NCT01382940 · Phase 4 · registry result, not featured evidence
5.6%
NCT01000610 · Phase 4 · registry result, not featured evidence
—1000 mg
NCT00934648 · Phase 4 · registry result, not featured evidence
—
NCT00502853 · Phase 4 · registry result, not featured evidence · combination
—
NCT00504777 · Phase 4 · registry result, not featured evidence · combination
—1000 mg
NCT00424502 · Phase 4 · registry result, not featured evidence
—
NCT00462345 · Phase 4 · registry result, not featured evidence · combination
7.5%
NCT02097745 · Phase 3 · registry result, not featured evidence
2.3%
NCT00503425 · Phase 3 · registry result, not featured evidence
—1000 mg
NCT00578305 · Phase 3 · registry result, not featured evidence
—1000 mg
NCT00578305 · Phase 3 · registry result, not featured evidence
—1000 mg
NCT00578305 · Phase 3 · registry result, not featured evidence
—1000 mg
NCT00578305 · Phase 3 · registry result, not featured evidence
—500 mg
NCT00578305 · Phase 3 · registry result, not featured evidence
—500 mg
NCT00578305 · Phase 3 · registry result, not featured evidence
—500 mg
NCT00578305 · Phase 3 · registry result, not featured evidence
—500 mg
NCT00578305 · Phase 3 · registry result, not featured evidence
0%Decreased Dose
NCT00422383 · Phase 3 · registry result, not featured evidence · combination
2.5%Escalated Dose
NCT00422383 · Phase 3 · registry result, not featured evidence · combination
1.1%High Dose
NCT00422383 · Phase 3 · registry result, not featured evidence · combination
—Low Dose
NCT00422383 · Phase 3 · registry result, not featured evidence · combination
1.2%1000 mg
NCT00443651 · Phase 3 · registry result, not featured evidence
3.4%500 mg
NCT00443651 · Phase 3 · registry result, not featured evidence
4.9%1000 mg
NCT01126541 · Phase 3 · registry result, not featured evidence
—1000 mg
NCT01126541 · Phase 3 · registry result, not featured evidence
2.7%1000 mg x 2
NCT01126541 · Phase 3 · registry result, not featured evidence
—
NCT00502840 · Phase 3 · registry result, not featured evidence · background therapy
30%
NCT00578565 · Phase 3 · registry result, not featured evidence
—
NCT02079532 · Phase 3 · registry result, not featured evidence · combination
—Initial Treatment: Rituximab + MTX
NCT01272908 · Phase 3 · registry result, not featured evidence · combination
—Re-treatment: Rituximab + MTX
NCT01272908 · Phase 3 · registry result, not featured evidence · combination
0.9%
NCT00502996 · Phase 3 · registry result, not featured evidence
—
NCT02006706 · Phase 3 · registry result, not featured evidence · combination
5.6%
NCT02093026 · Phase 2 · registry result, not featured evidence
0%Rituximab + Methotrexate (Group A)
NCT00282308 · Phase 2 · registry result, not featured evidence · combination
—Rituximab + Methotrexate (Group A)
NCT00282308 · Phase 2 · registry result, not featured evidence · combination
—
NCT00147966 · Phase 2 · registry result, not featured evidence
9.5%1000 mg
NCT00243412 · Phase 2 · registry result, not featured evidence
19%500 mg
NCT00243412 · Phase 2 · registry result, not featured evidence
—Rituximab-EU: by the End of Course
NCT01643928 · Phase na · registry result, not featured evidence
—Rituximab-US: by the End of Course
NCT01643928 · Phase na · registry result, not featured evidence
—
NCT00844714 · Phase na · registry result, not featured evidence
Serious AEs
6.8%h
NCT01526057 · Phase 2 · Rheumatoid Arthritis · phase 2
show 12 more results
6.1%PF-05280586 (EU): by the End of Co
NCT01643928 · Phase na · registry result, not featured evidence
12.9%PF-05280586 (EU): by the End of Co
NCT01643928 · Phase na · registry result, not featured evidence
13.3%PF-05280586 (EU): by the End of Co
NCT01643928 · Phase na · registry result, not featured evidence
6.7%PF-05280586 (US): by the End of Co
NCT01643928 · Phase na · registry result, not featured evidence
3.4%PF-05280586 (US): by the End of Co
NCT01643928 · Phase na · registry result, not featured evidence
3.4%PF-05280586 (US): by the End of Co
NCT01643928 · Phase na · registry result, not featured evidence
—PF-05280586/PF-05280586/PF-0528058
NCT01643928 · Phase na · registry result, not featured evidence
—PF-05280586/PF-05280586/PF-0528058
NCT01643928 · Phase na · registry result, not featured evidence
—PF-05280586/PF-05280586/PF-0528058
NCT01643928 · Phase na · registry result, not featured evidence
6.9%PF-05280586: by the End of Course
NCT01643928 · Phase na · registry result, not featured evidence
11.1%PF-05280586: by the End of Course
NCT01643928 · Phase na · registry result, not featured evidence
8.3%PF-05280586: by the End of Course
NCT01643928 · Phase na · registry result, not featured evidence
16.2%i
NCT00468546 · Phase 3 · combination
show 48 more results
13.1%
NCT00266227 · Phase 3
22.1%1.0 g x 2
NCT00299104 · Phase 3 · combination
15.5%0.5 g x 2
NCT00299104 · Phase 3 · combination
27.1%1.0 g
NCT00299130 · Phase 3 · combination
—2 x 1.0 g
NCT00299130 · Phase 3 · combination
31.1%2 x 0.5 g
NCT00299130 · Phase 3 · combination
8.5%
NCT01382940 · Phase 4 · registry result, not featured evidence
33.3%
NCT01000610 · Phase 4 · registry result, not featured evidence
0%1000 mg
NCT00934648 · Phase 4 · registry result, not featured evidence
20%
NCT00502853 · Phase 4 · registry result, not featured evidence · combination
8.3%
NCT00504777 · Phase 4 · registry result, not featured evidence · combination
0%1000 mg
NCT00424502 · Phase 4 · registry result, not featured evidence
15%
NCT00462345 · Phase 4 · registry result, not featured evidence · combination
58.8%
NCT02097745 · Phase 3 · registry result, not featured evidence
33.5%
NCT00503425 · Phase 3 · registry result, not featured evidence
—1000 mg
NCT00578305 · Phase 3 · registry result, not featured evidence
6.7%1000 mg
NCT00578305 · Phase 3 · registry result, not featured evidence
10.6%1000 mg
NCT00578305 · Phase 3 · registry result, not featured evidence
1.9%1000 mg
NCT00578305 · Phase 3 · registry result, not featured evidence
—500 mg
NCT00578305 · Phase 3 · registry result, not featured evidence
4.8%500 mg
NCT00578305 · Phase 3 · registry result, not featured evidence
6%500 mg
NCT00578305 · Phase 3 · registry result, not featured evidence
0%500 mg
NCT00578305 · Phase 3 · registry result, not featured evidence
12%Decreased Dose
NCT00422383 · Phase 3 · registry result, not featured evidence · combination
17.6%Escalated Dose
NCT00422383 · Phase 3 · registry result, not featured evidence · combination
17.2%High Dose
NCT00422383 · Phase 3 · registry result, not featured evidence · combination
11.2%Low Dose
NCT00422383 · Phase 3 · registry result, not featured evidence · combination
12%1000 mg
NCT00443651 · Phase 3 · registry result, not featured evidence
15.3%500 mg
NCT00443651 · Phase 3 · registry result, not featured evidence
19.8%1000 mg
NCT01126541 · Phase 3 · registry result, not featured evidence
28.8%1000 mg
NCT01126541 · Phase 3 · registry result, not featured evidence
36.8%1000 mg x 2
NCT01126541 · Phase 3 · registry result, not featured evidence
24.4%
NCT00502840 · Phase 3 · registry result, not featured evidence · background therapy
20%
NCT00578565 · Phase 3 · registry result, not featured evidence
11.9%
NCT02079532 · Phase 3 · registry result, not featured evidence · combination
10%Initial Treatment: Rituximab + MTX
NCT01272908 · Phase 3 · registry result, not featured evidence · combination
9.1%Re-treatment: Rituximab + MTX
NCT01272908 · Phase 3 · registry result, not featured evidence · combination
5.2%
NCT00502996 · Phase 3 · registry result, not featured evidence
14.3%
NCT02006706 · Phase 3 · registry result, not featured evidence · combination
49.5%
NCT02093026 · Phase 2 · registry result, not featured evidence
—Rituximab + Methotrexate (Group A)
NCT00282308 · Phase 2 · registry result, not featured evidence · combination
4.4%Rituximab + Methotrexate (Group A)
NCT00282308 · Phase 2 · registry result, not featured evidence · combination
8.3%
NCT00147966 · Phase 2 · registry result, not featured evidence
10%1000 mg
NCT00243412 · Phase 2 · registry result, not featured evidence
14.3%500 mg
NCT00243412 · Phase 2 · registry result, not featured evidence
6.3%Rituximab-EU: by the End of Course
NCT01643928 · Phase na · registry result, not featured evidence
3.3%Rituximab-US: by the End of Course
NCT01643928 · Phase na · registry result, not featured evidence
0%
NCT00844714 · Phase na · registry result, not featured evidence
Most frequent reported AEs
h
upper respiratory tract infection 9.6%
fatigue 6.8%
hypertension 5.5%
NCT01526057 · Phase 2 · Rheumatoid Arthritis · phase 2
show 9 more results
rheumatoid arthritis 9.1%
vomiting 6.1%
back pain 3%
NCT01643928 · Phase na · registry result, not featured evidence
rheumatoid arthritis 9.7%
back pain 6.5%
sinusitis 6.5%
NCT01643928 · Phase na · registry result, not featured evidence
rheumatoid arthritis 10%
urinary tract infection 10%
arthralgia 6.7%
NCT01643928 · Phase na · registry result, not featured evidence
diarrhoea 6.7%
oropharyngeal pain 6.7%
gastroenteritis 3.3%
NCT01643928 · Phase na · registry result, not featured evidence
diarrhoea 6.9%
nausea 6.9%
oropharyngeal pain 6.9%
NCT01643928 · Phase na · registry result, not featured evidence
upper respiratory tract infection 10.3%
alanine aminotransferase increased 6.9%
aspartate aminotransferase increased 6.9%
NCT01643928 · Phase na · registry result, not featured evidence
rheumatoid arthritis 6.9%
urinary tract infection 6.9%
fatigue 5.2%
NCT01643928 · Phase na · registry result, not featured evidence
rheumatoid arthritis 9.3%
urinary tract infection 9.3%
bronchitis 7.4%
NCT01643928 · Phase na · registry result, not featured evidence
bronchitis 10.4%
rheumatoid arthritis 10.4%
urinary tract infection 10.4%
NCT01643928 · Phase na · registry result, not featured evidence
i
rheumatoid arthritis 34.4% (placebo 41.8%)
upper respiratory tract infection 11.7% (placebo 8.2%)
headache 10.1% (placebo 10.1%)
NCT00468546 · Phase 3 · combination
show 42 more results
rheumatoid arthritis 23.1% (placebo 38.1%)
upper respiratory tract infection 22.2% (placebo 20.6%)
headache 15.9% (placebo 11.6%)
NCT00266227 · Phase 3
1.0 g x 2
infusion related reaction 25.5% (placebo 21.3%)
upper respiratory tract infection 22.1% (placebo 17.7%)
nasopharyngitis 19.8% (placebo 17.3%)
NCT00299104 · Phase 3 · combination
0.5 g x 2
infusion related reaction 19.8% (placebo 21.3%)
upper respiratory tract infection 17% (placebo 17.7%)
nasopharyngitis 15.2% (placebo 17.3%)
NCT00299104 · Phase 3 · combination
1.0 g
infusion related reaction 34.7% (placebo 19.2%)
upper respiratory tract infection 29.4% (placebo 7.6%)
nasopharyngitis 24.7% (placebo 9.9%)
NCT00299130 · Phase 3 · combination
2 x 0.5 g
infusion related reaction 35.3% (placebo 19.2%)
upper respiratory tract infection 35.3% (placebo 7.6%)
rheumatoid arthritis 29.3% (placebo 17.4%)
NCT00299130 · Phase 3 · combination
headache 5.7%
upper respiratory tract infection 5.4%
NCT01382940 · Phase 4 · registry result, not featured evidence
hypertension 11.1%
blurred vision 5.6%
dyspnea stage 2 5.6%
NCT01000610 · Phase 4 · registry result, not featured evidence
1000 mg
difficulty breathing 6.7%
diffuse skin rash 6.7%
dyspnea 6.7%
NCT00934648 · Phase 4 · registry result, not featured evidence
influenza 30%
pharyngitis 30%
alanine aminotransferase increased 20%
NCT00502853 · Phase 4 · registry result, not featured evidence · combination
upper respiratory tract infection 22.2%
cough 13.9%
dizziness 5.6%
NCT00504777 · Phase 4 · registry result, not featured evidence · combination
1000 mg
fever 10%
throat pain 10%
upper respiratory tract infection 10%
NCT00424502 · Phase 4 · registry result, not featured evidence
upper respiratory tract infection 30%
rash 15%
arthralgia 12.5%
NCT00462345 · Phase 4 · registry result, not featured evidence · combination
rheumatoid arthritis 64.8% (placebo 40.7%)
infusion related reaction 46.3% (placebo 18.6%)
upper respiratory tract infection 39.4% (placebo 10%)
NCT02097745 · Phase 3 · registry result, not featured evidence
back pain 13.4%
rheumatoid arthritis 12%
vitamin d deficiency 10.5%
NCT00503425 · Phase 3 · registry result, not featured evidence
1000 mg
bronchitis 8.3% (placebo 3.2%)
back pain 6.7% (placebo 1.6%)
upper respiratory tract infection 6.7% (placebo 1.6%)
NCT00578305 · Phase 3 · registry result, not featured evidence
1000 mg
arthralgia 0% (placebo 1.6%)
back pain 0% (placebo 1.6%)
bronchitis 0% (placebo 3.2%)
NCT00578305 · Phase 3 · registry result, not featured evidence
1000 mg
arthralgia 0% (placebo 1.6%)
back pain 0% (placebo 1.6%)
bronchitis 0% (placebo 3.2%)
NCT00578305 · Phase 3 · registry result, not featured evidence
500 mg
arthralgia 6.5% (placebo 1.6%)
bronchitis 6.5% (placebo 3.2%)
headache 6.5% (placebo 1.6%)
NCT00578305 · Phase 3 · registry result, not featured evidence
500 mg
arthralgia 0% (placebo 1.6%)
back pain 0% (placebo 1.6%)
bronchitis 0% (placebo 3.2%)
NCT00578305 · Phase 3 · registry result, not featured evidence
500 mg
arthralgia 0% (placebo 1.6%)
back pain 0% (placebo 1.6%)
bronchitis 0% (placebo 3.2%)
NCT00578305 · Phase 3 · registry result, not featured evidence
Decreased Dose
infusion related reaction 36%
nasopharyngitis 28%
rheumatoid arthritis 28%
NCT00422383 · Phase 3 · registry result, not featured evidence · combination
Escalated Dose
infusion related reaction 37.8%
upper respiratory tract infection 31.1%
rheumatoid arthritis 27.7%
NCT00422383 · Phase 3 · registry result, not featured evidence · combination
High Dose
infusion related reaction 38.7%
rheumatoid arthritis 32.3%
upper respiratory tract infection 30.1%
NCT00422383 · Phase 3 · registry result, not featured evidence · combination
Low Dose
infusion related reaction 43.3%
rheumatoid arthritis 32.1%
upper respiratory tract infection 29.1%
NCT00422383 · Phase 3 · registry result, not featured evidence · combination
1000 mg
upper respiratory tract infection 12.7%
rheumatoid arthritis 12.5%
arthralgia 11.7%
NCT00443651 · Phase 3 · registry result, not featured evidence
500 mg
rheumatoid arthritis 15.9%
upper respiratory tract infection 15.3%
headache 14.2%
NCT00443651 · Phase 3 · registry result, not featured evidence
1000 mg
urinary tract infection 17.3%
bronchitis 13.6%
headache 12.3%
NCT01126541 · Phase 3 · registry result, not featured evidence
1000 mg
bronchitis 19.7%
asthenia 16.7%
cough 16.7%
NCT01126541 · Phase 3 · registry result, not featured evidence
1000 mg x 2
bronchitis 23.5%
rheumatoid arthritis 17.6%
urinary tract infection 17.6%
NCT01126541 · Phase 3 · registry result, not featured evidence
nasopharyngitis 22.3%
bronchitis 8.8%
upper respiratory tract infection 6.2%
NCT00502840 · Phase 3 · registry result, not featured evidence · background therapy
infusion reaction 10%
NCT00578565 · Phase 3 · registry result, not featured evidence
nasopharyngitis 12.3%
cough 6.3%
hypertension 5.6%
NCT02079532 · Phase 3 · registry result, not featured evidence · combination
rheumatoid arthritis 16.7%
nausea 14.2%
headache 11.7%
NCT01272908 · Phase 3 · registry result, not featured evidence · combination
nausea 11.7%
nasopharyngitis 10.4%
headache 7.8%
NCT01272908 · Phase 3 · registry result, not featured evidence · combination
headache 17.2%
urinary tract infection 9.9%
nausea 9.5%
NCT00502996 · Phase 3 · registry result, not featured evidence
rheumatoid arthritis 50.8% (placebo 42.5%)
infusion related reaction 43.7% (placebo 19.7%)
upper respiratory tract infection 32.9% (placebo 5.5%)
NCT02093026 · Phase 2 · registry result, not featured evidence
rheumatoid arthritis 17.6%
headache 13.2%
pruritus 13.2%
NCT00282308 · Phase 2 · registry result, not featured evidence · combination
allergic reaction to detergent on hand and arm 4.2%
anemia 4.2%
contact dimities 4.2%
NCT00147966 · Phase 2 · registry result, not featured evidence
1000 mg
upper respiratory tract infection 35%
cough 15%
insomnia 15%
NCT00243412 · Phase 2 · registry result, not featured evidence
500 mg
sinusitis 28.6%
arthralgia 23.8%
nausea 23.8%
NCT00243412 · Phase 2 · registry result, not featured evidence
upper respiratory tract infection 9.4%
bronchitis 3.1%
fall 3.1%
NCT01643928 · Phase na · registry result, not featured evidence
arthralgia 10%
asthenia 6.7%
back pain 6.7%
NCT01643928 · Phase na · registry result, not featured evidence

Notes

  1. aTrial phases differ: Phase 3 versus Phase 2.
  2. bPopulation comparability has not been reviewed for both studies.
  3. cTreatment context has not been resolved for both arms.
  4. dAssessment timepoints differ: 52 weeks versus 25 weeks.
  5. eThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  6. fAssessment timepoints differ: 48 weeks versus 25 weeks.
  7. gTrial phases differ: Phase 3 versus Phase na.
  8. hPopulation comparability has not been reviewed for 12 of these studies.
  9. iPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

PF-05280586

EULAR Moderate 33.3% (n=73) vs 35.1% (n=74) Rituximab @ 3wk
responder rate · % of participants
NCT01526057 · Phase 2 · Rheumatoid Arthritis · phase 2
show 6 more results
47.9% (n=73) vs 39.4% (n=74) Rituximab @ 5wk
NCT01526057 · Phase 2 · Rheumatoid Arthritis · phase 2
45.6% (n=73) vs 43.8% (n=74) Rituximab @ 9wk
NCT01526057 · Phase 2 · Rheumatoid Arthritis · phase 2
38.8% (n=73) vs 37.5% (n=74) Rituximab @ 13wk
NCT01526057 · Phase 2 · Rheumatoid Arthritis · phase 2
45.5% (n=73) vs 39.4% (n=74) Rituximab @ 17wk
NCT01526057 · Phase 2 · Rheumatoid Arthritis · phase 2
51.7% (n=73) vs 46.2% (n=74) Rituximab @ 21wk
NCT01526057 · Phase 2 · Rheumatoid Arthritis · phase 2
50% (n=73) vs 46.6% (n=74) Rituximab @ 25wk
NCT01526057 · Phase 2 · Rheumatoid Arthritis · phase 2
DAS Remission 8.7% (n=73) vs 4.1% (n=74) Rituximab @ 3wk
responder rate · % of participants
NCT01526057 · Phase 2 · Rheumatoid Arthritis · phase 2
show 6 more results
16.9% (n=73) vs 8.5% (n=74) Rituximab @ 5wk
NCT01526057 · Phase 2 · Rheumatoid Arthritis · phase 2
26.5% (n=73) vs 20.5% (n=74) Rituximab @ 9wk
NCT01526057 · Phase 2 · Rheumatoid Arthritis · phase 2
28.4% (n=73) vs 29.2% (n=74) Rituximab @ 13wk
NCT01526057 · Phase 2 · Rheumatoid Arthritis · phase 2
25.8% (n=73) vs 25.4% (n=74) Rituximab @ 17wk
NCT01526057 · Phase 2 · Rheumatoid Arthritis · phase 2
25% (n=73) vs 16.9% (n=74) Rituximab @ 21wk
NCT01526057 · Phase 2 · Rheumatoid Arthritis · phase 2
28% (n=73) vs 24.1% (n=74) Rituximab @ 25wk
NCT01526057 · Phase 2 · Rheumatoid Arthritis · phase 2
DAS28-CRP -1.24 vs -1.86 Rituximab-EU score @ 1wk
absolute change · score
Change at Course 1/Week 1
NCT01643928 · Phase na · registry result, not featured evidence
show 2 more results
-1.94 vs -1.86 Rituximab-EU score @ 1wk
Change at Course 1/Week 1
NCT01643928 · Phase na · registry result, not featured evidence
-1.95 vs -1.86 Rituximab-EU score @ 1wk
Change at Course 1/Week 1
NCT01643928 · Phase na · registry result, not featured evidence
DAS28-CRP -2.03 vs -2.59 Rituximab-EU score @ 6wk
absolute change · score
Change at Course 1/Week 6
NCT01643928 · Phase na · registry result, not featured evidence
show 2 more results
-2.54 vs -2.59 Rituximab-EU score @ 6wk
Change at Course 1/Week 6
NCT01643928 · Phase na · registry result, not featured evidence
-2.66 vs -2.59 Rituximab-EU score @ 6wk
Change at Course 1/Week 6
NCT01643928 · Phase na · registry result, not featured evidence
DAS28-CRP -2.37 vs -2.78 Rituximab-EU score @ 13wk
absolute change · score
Change at Course 1/Week 13
NCT01643928 · Phase na · registry result, not featured evidence
show 2 more results
-2.66 vs -2.78 Rituximab-EU score @ 13wk
Change at Course 1/Week 13
NCT01643928 · Phase na · registry result, not featured evidence
-2.76 vs -2.78 Rituximab-EU score @ 13wk
Change at Course 1/Week 13
NCT01643928 · Phase na · registry result, not featured evidence
DAS28-CRP -2.35 vs -2.32 Rituximab-EU score @ 25wk
absolute change · score
Change at Course 1/Week 25
NCT01643928 · Phase na · registry result, not featured evidence
show 2 more results
-2.24 vs -2.32 Rituximab-EU score @ 25wk
Change at Course 1/Week 25
NCT01643928 · Phase na · registry result, not featured evidence
-2.5 vs -2.32 Rituximab-EU score @ 25wk
Change at Course 1/Week 25
NCT01643928 · Phase na · registry result, not featured evidence
DAS28-CRP -1.98 score @ 1wk
absolute change · score
No placebo or comparator arm
Change at Course 2/Week 1
NCT01643928 · Phase na · registry result, not featured evidence
show 2 more results
-1.92 score @ 1wk
Change at Course 2/Week 1
NCT01643928 · Phase na · registry result, not featured evidence
-2.34 score @ 1wk
Change at Course 2/Week 1
NCT01643928 · Phase na · registry result, not featured evidence
DAS28-CRP -2.66 score @ 6wk
absolute change · score
No placebo or comparator arm
Change at Course 2/Week 6
NCT01643928 · Phase na · registry result, not featured evidence
show 2 more results
-2.75 score @ 6wk
Change at Course 2/Week 6
NCT01643928 · Phase na · registry result, not featured evidence
-3 score @ 6wk
Change at Course 2/Week 6
NCT01643928 · Phase na · registry result, not featured evidence
DAS28-CRP -2.35 score @ 13wk
absolute change · score
No placebo or comparator arm
Change at Course 2/Week 13
NCT01643928 · Phase na · registry result, not featured evidence
show 2 more results
-2.65 score @ 13wk
Change at Course 2/Week 13
NCT01643928 · Phase na · registry result, not featured evidence
-3.21 score @ 13wk
Change at Course 2/Week 13
NCT01643928 · Phase na · registry result, not featured evidence
DAS28-CRP -2.3 score @ 25wk
absolute change · score
No placebo or comparator arm
Change at Course 2/Week 25
NCT01643928 · Phase na · registry result, not featured evidence
show 2 more results
-2.42 score @ 25wk
Change at Course 2/Week 25
NCT01643928 · Phase na · registry result, not featured evidence
-2.82 score @ 25wk
Change at Course 2/Week 25
NCT01643928 · Phase na · registry result, not featured evidence
DAS28-CRP -1.98 score @ 1wk
absolute change · score
No placebo or comparator arm
Change at Course 3/Week 1
NCT01643928 · Phase na · registry result, not featured evidence
show 2 more results
-2.33 score @ 1wk
Change at Course 3/Week 1
NCT01643928 · Phase na · registry result, not featured evidence
-2.51 score @ 1wk
Change at Course 3/Week 1
NCT01643928 · Phase na · registry result, not featured evidence
DAS28-CRP -2.46 score @ 13wk
absolute change · score
No placebo or comparator arm
Change at Course 3/Week 13
NCT01643928 · Phase na · registry result, not featured evidence
show 2 more results
-2.74 score @ 13wk
Change at Course 3/Week 13
NCT01643928 · Phase na · registry result, not featured evidence
-3.03 score @ 13wk
Change at Course 3/Week 13
NCT01643928 · Phase na · registry result, not featured evidence

+ 86 further endpoints in the CSV export.

Rituximab

DAS28-ESR -3.46 vs -2.33 placebo score @ 52wk1.0 g x 2
absolute change · score
NCT00299104 · Phase 3 · combination
show 5 more results
-1.68 vs -0.76 placebo score @ 24wk2 x 1.0 g
NCT00299130 · Phase 3 · combination
-3.35 vs -2.33 placebo score @ 52wk0.5 g x 2
NCT00299104 · Phase 3 · combination
-1.71 vs -0.76 placebo score @ 24wk2 x 0.5 g
NCT00299130 · Phase 3 · combination
-1.9 vs -0.4 placebo score @ 24wk
NCT00468546 · Phase 3 · combination
-2.1 vs -1.8 placebo score @ 48wk
NCT00266227 · Phase 3
DAS28 Low Disease Activity 12.4% (n=170) vs 4.7% (n=172) placebo @ 24wk2 x 1.0 g
responder rate · % of participants
Low disease activity
NCT00299130 · Phase 3 · combination
show 4 more results
24.3% (n=169) vs 18.1% (n=171) placebo @ 48wk2 x 1.0 g
Low Disease Activity
NCT00299130 · Phase 3 · combination
17.5% (n=166) vs 4.7% (n=172) placebo @ 24wk2 x 0.5 g
Low Disease Activity
NCT00299130 · Phase 3 · combination
20% (n=165) vs 18.1% (n=171) placebo @ 48wk2 x 0.5 g
Low Disease Activity
NCT00299130 · Phase 3 · combination
15% (n=298) vs 2% (n=201) placebo @ 24wk
Low disease activity
NCT00468546 · Phase 3 · combination
DAS28-ESR Remission 9% (n=298) vs 0% (n=201) placebo @ 24wk
responder rate · % of participants
Remission
NCT00468546 · Phase 3 · combination
EULAR Moderate 50% (n=298) vs 19.9% (n=201) placebo @ 24wk
responder rate · % of participants
Moderate response
NCT00468546 · Phase 3 · combination · converted to % from 149 participants as posted
show 1 more result
47.5% (n=318) vs 42.7% (n=157) placebo @ 48wk
Moderate Response
NCT00266227 · Phase 3
EULAR Good 20.6% (n=170) vs 16.9% (n=172) placebo @ 48wk2 x 1.0 g
responder rate · % of participants
Good response
NCT00299130 · Phase 3 · combination
show 3 more results
19.8% (n=167) vs 16.9% (n=172) placebo @ 48wk2 x 0.5 g
Good Response
NCT00299130 · Phase 3 · combination
14.8% (n=298) vs 2% (n=201) placebo @ 24wk*
Good response
NCT00468546 · Phase 3 · combination · converted to % from 44 participants as posted
20.8% (n=318) vs 18.5% (n=157) placebo @ 48wk
Good Response
NCT00266227 · Phase 3
SF-36 Physical Component Summary 5.8 vs 0.9 placebo score @ 24wk
absolute change · score
Physical score
NCT00468546 · Phase 3 · combination
ACR50 28.9% (n=318) vs 26.1% (n=157) placebo @ 48wk
responder rate · % of participants
ACR50
NCT00266227 · Phase 3 · converted to % from 92 Participants as posted
ACR70 13.8% (n=318) vs 13.4% (n=157) placebo @ 48wk
responder rate · % of participants
ACR70
NCT00266227 · Phase 3 · converted to % from 44 Participants as posted
Swollen Joint Count -12.5 vs -10.2 placebo count @ 48wk
absolute change · count
NCT00266227 · Phase 3
Tender Joint Count -15.3 vs -14.7 placebo count @ 48wk
absolute change · count
NCT00266227 · Phase 3
Patient Global Assessment -26.9 vs -23 placebo mm @ 48wk
absolute change · mm
NCT00266227 · Phase 3
Physician Global Assessment -31.5 vs -25.5 placebo mm @ 48wk
absolute change · mm
NCT00266227 · Phase 3

+ 288 further endpoints in the CSV export.

Follicular Lymphoma

Shared mechanism: CD20 · full Follicular Lymphoma pipeline

PF-05280586

Marketed by Pfizer

Approved in Follicular Lymphomabiologic (registry-typed, subtype undisclosed)
Reliable signal

NCT02213263 · Phase 3 · completed

The trial randomized 394 participants to PF-05280586 or active comparator MabThera and was double-blind. The primary endpoint was the clinical response rate at Week 26, and the prespecified equivalence margin was met because the 95% confidence interval for the response-rate difference (-4.16% to 13.47%) remained within the -16% to 16% limits.

Reported efficacy

Overall Response Rate (ORR): Percentage of Participants With Overall Response (OR) at Week 26: Overall Response Rate (ORR): Percentage of Participants With Overall Response (OR) at Week 26 (Week 26): Rituximab-EU 70.7 percentage of participants (95% CI 63.8 to 76.9) | PF-05280586 75.5 percentage of participants (95% CI 68.9 to 81.4) (met)

Result source: NCT02213263

Rituximab · Rituxan

Marketed by Roche and partners

Approved in Follicular Lymphomamonoclonal antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: December 2026 · NCT01479842 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Follicular Lymphoma

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Rituximab: registry results are on file for Follicular Lymphoma, but their comparison mappings are not yet available.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

PF-05280586
Overall Response Rate (ORR): Percentage of Participants With Overall Response (OR) at Week 26 (Week 26): Rituximab-EU 70.7 percentage of participants (95% CI 63.8 to 76.9) | PF-05280586 75.5 percentage of participants (95% CI 68.9 to 81.4) NCT02213263 · Phase 3 · design grade: strong · reviewed ClinicalTrials.gov result

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: PF-05280586's landscape · Rituximab's landscape